XML 22 R7.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Note 2 - Stock-based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2018
Notes to Financial Statements |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | Note 2 — Stock-Based Compensation As of March 31, 2018, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (“Incentive Plan”) and the Employee Stock Purchase Plan (“ESPP”). The Incentive Plan was amended and restated in April 2017 and approved by the Company’s stockholders in May 2017. The ESPP was amended and restated in March 2014 and approved by the Company’s stockholders in May 2014. Stock-based compensation expense of $2,903 ( $2,820 of expense related to the Incentive Plan and $83 of expense related to the ESPP) was recognized during the first three months of 2018, while $2,462 ( $2,326 of expense related to the Incentive Plan and $136 of expense related to the ESPP) was recognized during the first three months of 2017. There was approximately $15,717 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March 31, 2018. That cost is expected to be recognized as follows: $5,475 during the remainder of 2018, $5,472 in 2019, $3,386 in 2020, $1,382 in 2021 and $2 in 2022. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred and the award vests. Stock Incentive Plan The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Stock option awards granted to employees generally vest 25% each year until fully vested after four years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2018, 75% of the August 2013 grants have vested based upon achievement of three milestones: ( 1 ) successful completion of the OPuS- 1 clinical trial, for which vesting occurred in the second quarter of 2014, ( 2 ) FDA approval of RAPIVAB, for which vesting occurred in the fourth quarter of 2014, and ( 3 ) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. As of March 31, 2018, 30% of the December 2014 grants have vested based upon achievement of successful completion of a hereditary angioedema (“HAE”) patient trial with a 2 nd generation compound, for which vesting occurred in August 2017. Thus, as of March 31, 2018, 25% of the August 2013 performance-based grants and 70% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10 years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. Related activity under the Incentive Plan is as follows:
|  | Awards Available |  | Options Outstanding |  | Weighted Average Exercise Price
Balance December 31, 2017 |  |  | 468 |  |  |  | 14,452 |  |  | $ | 6.06 |
Restricted stock unit awards granted |  |  | (6 | ) |  |  | — |  |  |  | — |
Restricted stock unit awards cancelled |  |  | — |  |  |  | — |  |  |  | — |
Stock option awards granted |  |  | (31 | ) |  |  | 31 |  |  |  | 5.43 |
Stock option awards exercised |  |  | — |  |  |  | (169 | ) |  |  | 3.22 |
Stock option awards cancelled |  |  | 45 |  |  |  | (45 | ) |  |  | 5.87 |
Balance March 31, 2018 |  |  | 476 |  |  |  | 14,269 |  |  | $ | 6.10 |
As of March 31, 2018, there were 48 restricted stock unit awards outstanding. For stock option awards granted under the Incentive Plan during the first three months of 2018, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first three months of 2018 and 2017 was $3.72 and$3.75, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first three months of 2018. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company’s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero -coupon government issues with a remaining term equal to the expected term. Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan
|  | 2018
Expected Life in Years |  |  | 5.5 |
Expected Volatility |  |  | 82 | %
Expected Dividend Yield |  |  | 0.0 | %
Risk-Free Interest Rate |  |  | 2.4 | %
Employee Stock Purchase Plan (“ESPP”) The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 277 shares remain available for purchase at March 31, 2018. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six -month purchase intervals. No more than 3 shares may be purchased by any one employee at the six -month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 49 shares during the first three months of 2018 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the “look-back” option were determined using a Black-Scholes option pricing model.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration